This year’s meeting was not defined by incremental adjustments, it’s marked by biological inflection points. Renal cell carcinoma is transitioning from VEGF-dominant management towards therapeutic ecosystems integrating immunotherapy, HIF-2α inhibition, rational plus IO sequencing, and increasingly sophisticated biomarker development. The common thread across presentations was refinement – refinement of risk, refinement of sequencing and biological targeting.
In advanced disease after prior immunotherapy, the most practice-impacting data came from LITESPARK-011, presented by Dr Robert Motzer. This phase III trial directly addressed one of the most critical unanswered questions in contemporary renal cell carcinoma – what is the optimal therapy after progression on anti-PD-L1-based treatment? In this study 747 patients with advanced clear cell renal cell carcinoma progressing after prior anti-PD-L1 therapy were randomised to belzutifan plus lenvatinib versus cabozantinib. Belzutifan, a HIF-2α inhibitor, combined with VEGFR blockade demonstrated statistically significant improvement in progression free survival compared with cabozantinib at both interim analyses. Objective response rate was also superior in the combination arm – the median duration of response at the second interim analysis reached 23 months with belzutifan plus lenvatinib compared with 12.3 months with cabozantinib. Overall survival numerically favoured the combination, although statistical significance has not yet been reached and follow-up continues.
Importantly, this represents the first phase III in renal cell carcinoma showing improved outcomes versus a contemporary VEGFR TKI in the post-IO setting and the first phase III validation of a HIF-2α inhibitor combined with VEGF blockade. This is not simply another regimen, it introduces a new biological axis into standard sequencing. This significance of HIF-2α targeting extends beyond refractory disease. Dr Toni Choueiri presented LITESPARK-022, a randomised phase III trial evaluating adjuvant pembrolizumab plus belzutifan versus pembrolizumab alone in patients with clear cell renal cell carcinoma at increased risk of recurrence after nephrectomy. Over 1,800 patients were randomised. The combination significantly improved disease free survival with a hazard ratio of 0.72 and highly significant p-value. The estimated 24-months disease free survival rate was 80.7% with pembrolizumab plus belzutifan versus 73.7% with pembrolizumab alone. Overall survival remains immature. Toxicity reflected the known profile of belzutifan, including anaemia and hypoxia, with grade 3 or more adverse events occurring in approximately 52% of patients receiving the combination versus 30% with pembrolizumab alone.
These results suggest that HIF-2α inhibition may expand into earlier disease states and potentially redefine adjuvant standards pending longer-term survival data. If LITESPARK-011 establishes HIF-2α as a core post-IO strategy and LITESPARK-022 moves it into the adjuvant space, the conceptual message is clear. We are now directly targeting the hypoxia-driven transcriptional programme downstream of VHL loss, the molecular hallmark of clear cell renal cell carcinoma,across disease stages. This represents mechanistic moderation of the field.
In parallel an equally important development was the advancement of biomarker-driven risk stratification in oligometastatic disease. The K-COMPASS model evaluated circulating kidney injury molecule 1, or KIM-1, together with circulating tumour DNA in patients with oligometastatic clear cell renal cell carcinoma undergoing metastatic-directed therapy without systemic treatment. In this phase II trial both baseline and treatment scheme 1 levels were strongly associated with progression free and overall survival. Baseline KIM-1 was associated with overall survival with a hazard ratio exceeding 5. ctDNA minimal residual disease detection similarly correlated with systemic therapy free survival. By integrating KIM-1, ctDNA and clinical variables, including ECOG status, number of metastases, prior systemic therapy and time from diagnosis to metastasis, investigators developed the kidney cancer oligometastatic prognostic assessment systemic score. The model demonstrated stronger discrimination with a c-index of 0.76 and excellent calibration. This is the first time evaluation of KIM-1 and ctDNA in renal cell carcinoma and the first effort to contract a biomarker-integrated prognostic model specifically for oligometastatic disease. It opens the possibility of biologically informed de-escalation strategies in carefully selected patients rather than uniform systemic therapy.
Now, durability of immunotherapy responses remains a defining future of renal cell carcinoma biology. Long-term follow-up data from nivolumab plus ipilimumab in combinations, reinforced in discussions by investigators, including Dr David McDermott, continue to demonstrate that approximately 10-12% of patients achieve sustained complete responses. Although this proportion is modest, it represents a biologically distinct, immunologically sensitive subgroup. The challenge remains the absence of validated predictive biomarkers capable of prospectively identifying these patients. Transcriptomic and inflammatory gene signatures are promising but not yet practice defining.
Post-immunotherapy sequencing beyond HIF-2α combinations remains complex. Cabozantinib continues to demonstrate activity in refractory settings and lenvatinib plus everolimus remains a potent option. However, until LITESPARK-011 prospective randomised data in the modern post-PD-1 era were limited. The emergence of belzutifan-based combinations now forces a recalibration of second- and third-line sequencing algorithms. At a biological level intratumoral heterogeneity continues to shape therapeutic response and systemic dominant tumours may predefine response to VEGF-targeted strategies whereas inflammatory phenotypes may derive more benefit from immune checkpoint blockade. The integration of metabolic targeting through HIF-2α inhibition introduces a third axis into this treatment. The future of renal oncology lies in harmonising these axes – angiogenesis, immunity and hypoxia biology – rather than treating them sequentially without mechanistic consideration.
When looking at the overall data from ASCO GU 2026 in renal cell carcinoma, several conclusions emerge. First, HIF-2α inhibition has moved from a promising concept to a phase III validated platform across disease stages. Second, belzutifan plus lenvatinib establishes a new reference point in the post-anti-PD-L1 setting. Third, adjuvant intensification with belzutifan plus pembrolizumab meaningfully improves disease free survival. Four, biomarker integration through circulating KIM-1 and ctDNA represents a step forward biologically, informing risk stratification in oligometastatic disease. And, fifth, while immunotherapy durability remains central, predictive biomarker development remains an unmet need.
ASCO GU 2026 did not introduce a single disruptive molecule, instead it confirmed that renal cell carcinoma has entered an era of biological integration. The next advance will not be defined solely by adding drugs but by aligning different mechanisms, disease stages and molecular risk in accordant therapeutic sequences.
Thank you again for the opportunity to share these advances in renal cell carcinoma presented at ASCO GU 2026.
